Patents by Inventor Hajime Hiratani

Hajime Hiratani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5750650
    Abstract: A novel peptide having molecular weight of 31,000 (SDS-PAGE) is obtained from aqueous extract of Natto or the culture of Bacillus natto by purification procedures including alcohol fractionation and/or salting out and hydrophobic chromatography, and the physicochemical properties, including the amino acid sequence, of the peptide are determined.The peptide is active in fibrinolysis, exhibits strong thrombolytic activity by oral administration and is useful as an oral thrombolytic agent.
    Type: Grant
    Filed: May 24, 1993
    Date of Patent: May 12, 1998
    Inventors: Koichiro Nakanishi, Keiichi Nomura, Kyoko Tajima, Hajime Hiratani, Kazuo Kato
  • Patent number: 5403731
    Abstract: A modified superoxide dismutase represented by the formula: ##STR1## (wherein R is as defined below; SOD is a residue of superoxide dismutase) is produced, in a shortened period of reaction with a high and constant modification ratio, by reacting a polymeric carbonyldiimidazole derivative represented by the formula: ##STR2## (wherein R is a residue of a water soluble polymer having an average molecular weight of about 2,000 to 10,000) with superoxide dismutase in the presence of a buffer having a pH of 9.0 to 11.0 and a concentration of 0.1 M to 0.5 M, preferably 0.2 M to 0.4 M, at a temperature of 30.degree. to 70.degree. C., preferably 45.degree. to 60.degree. C. The modified superoxide dismutase thus produced exhibits a suitably prolonged blood half-life.
    Type: Grant
    Filed: December 3, 1993
    Date of Patent: April 4, 1995
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Yoshiyuki Nakano, Hajime Hiratani, Kazuo Kato
  • Patent number: 5371196
    Abstract: Secretory immunoglobulin A preparations substantially not containing virus are produced by a process wherein secretory immunoglobulin A which might be contaminated with viruses is (1) heated about 60.degree. C. for about 10 hours, or (2) subjected to the reaction with tri-n-butyl phosphate and a surfactant and the heating as mentioned above, as liquidized form in an aqueous medium, and then polymerized matters are precipitated from the resulting solution by adding polyethyleneglycol thereto.
    Type: Grant
    Filed: September 1, 1993
    Date of Patent: December 6, 1994
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Yoshikazu Yuki, Motoko Baba, Mitsuo Shimizu, Kazuo Kato, Hajime Hiratani
  • Patent number: 5296223
    Abstract: There are provided thrombolytic agents suited for oral administration. The agent comprises a proteolytic enzyme of subtilisin family, such as subtilisin BPN', subtilisin Carsberg, subtilisin amylosacchariticus, etc., produced by microorganisms belonging to genus Bacillus, such as Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, etc. and, even when administered orally, exhibits thrombolytic activity.
    Type: Grant
    Filed: October 13, 1992
    Date of Patent: March 22, 1994
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Koichiro Nakanishi, Hajime Hiratani, Kazuo Kato
  • Patent number: 5283239
    Abstract: LEM which is an aqueous extract of a mycelial culture of Lentinus Edodes and has a sugar composition composed of arabinose, xylose, glucose, mannose, galasctose, fucose and rhamnose, as well as a fraction of LEM which corresponds to molecular weights of 10,000 to 1,000,000 daltons and has a sugar composition composed of arabinose, xylose, glucose, mannose and galactose are provided as agents for inhibiting the adsorption of herpesviruses such as herpes simplex to the cells.
    Type: Grant
    Filed: January 14, 1992
    Date of Patent: February 1, 1994
    Assignees: JCR Pharmaceuticals Co. Ltd., Noda Shokukin Kogyo Co., Ltd.
    Inventors: Junichi Koga, Yasuhiro Ohashi, Hajime Hiratani
  • Patent number: 5281577
    Abstract: An inhibitor of the proliferation of herpesviruses and of the recurrence of affections caused by their latent infection, which is an active material obtained by fractional purification of the aqueous extract from cultured Lentinus edodes mycelia.
    Type: Grant
    Filed: October 15, 1992
    Date of Patent: January 25, 1994
    Assignees: JCR Pharmaceuticals Co., Ltd., Noda Shokukin Kogyo Co., Ltd.
    Inventors: Junichi Koga, Yasuhiro Ohashi, Hajime Hiratani
  • Patent number: 5240864
    Abstract: Antiserum which can recognize all subtypes of human leukocyte interferon is prepared from the blood of an animal immunized with partially purified human leukocyte interferon obtained from a culture of human leukocyte stimulated with Sendai virus.The antiserum is added to a column whereon concentrated culture broth of human leukocyte has been immobilized to adsorb impurities, the effluent is added to a column whereon partially purified human leukocyte interferon has been immobilized to adsorb anti-human leukocyte interferon antibody and then the antibody is eluted from the column.The antibody thus obtained recognizes all subtypes of human leukocyte interferon and can be separated by a chromatography to each monoclonal antibody which recognizes a single subtype.Employing these antibodies, the subtypes of human leukocyte interferon or their antibodies in a sample can be analized or assayed.
    Type: Grant
    Filed: December 4, 1990
    Date of Patent: August 31, 1993
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Junichi Koga, Hiroyuki Shirono, Akio Matsuo, Hajime Hiratani
  • Patent number: 5173415
    Abstract: A membrane filter of 0.025 to 0.05 .mu. in pore size is treated by passing the solution of a water-soluble high molecular substance such as albumin, dextran, polyvinylpyrrolidone, polysorbate 80, gelatin or the like through the membrane filter. Employing the filter thus treated, the solution of a physiologically active substance of human origin such as human growth hormone, kallikrein, trypsin inhibitor, epidermal growth factor, leucocyte interferon etc. is filtered at high recovery rate of the active substance avoiding the adsorption of the active substance onto the filter. By the filtration, harmful viruses such as Creutzfeldt-Jacob disease pathogen which may exist in the physiologically active substance can be removed.
    Type: Grant
    Filed: January 14, 1991
    Date of Patent: December 22, 1992
    Assignee: Japan Chemical Research Co., Ltd.
    Inventors: Hajime Hiratani, Jun Tateishi, Tetsuyuki Kitamoto
  • Patent number: 4946785
    Abstract: The thermal degradation of urokinase in an aqueous solution is suppressed by heating an aqueous solution containing urokinase in the presence of citric acid or a water-soluble salt thereof such as sodium, potassium or lithium citrate at about 60.degree. C. for about 10 hours.
    Type: Grant
    Filed: June 17, 1988
    Date of Patent: August 7, 1990
    Assignee: Japan Chemical Research Co., Ltd.
    Inventors: Hajime Hiratani, Satoshi Nishimuro, Koichiro Nakanishi, Masaichi Ota, Hiroshi Matsumoto
  • Patent number: 4780209
    Abstract: Two components, trypsin and kallidinogenase, in human urine are concentrated simultaneously by allowing human urine at neutral pH, collecting bubbles thus formed to obtain the concentrate of the two components, adjusting the concentrate to weak acidity, contacting the acidified concentrate with chitosan to allow the two components to be adsorbed onto chitosan, eluting the components from the adsorbent with aqueous ammonia solution, and neutralizing and heating the eluate at about 60.degree. C. for about 10 hours to make the eluate virus-free, followed by separating the components from the eluate.
    Type: Grant
    Filed: October 2, 1987
    Date of Patent: October 25, 1988
    Assignee: Japan Chemical Research Co., Ltd.
    Inventors: Yoshikazu Yuki, Koichiro Nakanishi, Hajime Hiratani
  • Patent number: 4676983
    Abstract: A tumor cytostatic-cytocidal factor is produced by disrupting platelets, extracting the disrupted platelets with an acidic aqueous solution or an acidic water-organic solvent mixture, and, after gel filtration, if desired, to separate a fraction having an estimated molecular weight of 10,000 to 20,000 and having tumor cell growth inhibiting activity, subjecting said extract or said fraction to chromatography to isolate a cytostatic fraction having a molecular weight of 10,000 to 20,000 and an isoelectric point of 9.0 to 10.0, giving a positive nihidrin reaction and being such that it is deactivated by trypsin but not deactivated by heating in physiological saline solution at 60.degree. C. for 30 minutes or contacting at room temperature with 0.2N hydrochloric acid for 60 minutes or 70% formic acid for 30 minutes.
    Type: Grant
    Filed: March 21, 1986
    Date of Patent: June 30, 1987
    Assignee: Japan Chemical Research Co., Ltd.
    Inventors: Toyohiko Nishimura, Hajime Hiratani
  • Patent number: 4665161
    Abstract: Crude HCG is purified by extracting with a neutral or weakly basic aqueous solution containing lower aliphatic alcohol and soluble salt, adding lower aliphatic alcohol to the extracted solution to form precipitates and the precipitates containing high purity of HCG are collected. This precipitates can be further purified by dissolving in a buffer solution, contacting the solution with a weak anion exchanger and eluting the exchanger with said buffer solution containing added salt.
    Type: Grant
    Filed: April 21, 1986
    Date of Patent: May 12, 1987
    Assignee: Japan Chemical Research Co., Ltd.
    Inventors: Yoshikazu Yuki, Toyohiko Nishimura, Hajime Hiratani
  • Patent number: 4609546
    Abstract: A composition wherein a physiologically active polypeptide or a glycoprotein of human origin, for instance, urokinase, kallikrein or leukocyte interferon, is coupled to a polyoxyethylene-polyoxypropylene copolymer. The composition is effective in the human body for a prolonged period of time.
    Type: Grant
    Filed: June 23, 1983
    Date of Patent: September 2, 1986
    Assignee: Japan Chemical Research Co., Ltd.
    Inventor: Hajime Hiratani
  • Patent number: 4528186
    Abstract: A method for producing a human epidermal growth factor in high yield and high purity by adding particles of an aluminum or magnesium silicate of the formula z.2 (or 6) SiO.sub.2.xH.sub.2 O where Z is Al.sub.2 O.sub.3 or 2MgO and x is the number of water molecules in each molecule of the compound, to human urine under neutral to acid conditions to adsorb the factor on the particles and then eluting the factor with an alkaline solution.
    Type: Grant
    Filed: June 9, 1983
    Date of Patent: July 9, 1985
    Assignee: Japan Chemical Research Co., Ltd.
    Inventors: Toyohiko Nishimura, Naomi Uchida, Hajime Hiratani
  • Patent number: 4510248
    Abstract: Human urinary kallikrein is concentrated and purified by the following procedures; (a) Human urine is contacted with chitosan, a high molecular agglutinant obtained from chitin, at a pH from 4.0 to 7.0, thereby kallikrein is adsorbed on the chitosan and (b) kallikrein is eluted from the chitosan with an aqueous alkaline solution having a pH from 8.0 to 12.0.
    Type: Grant
    Filed: June 29, 1983
    Date of Patent: April 9, 1985
    Assignee: Japan Chemical Research Co., Ltd.
    Inventors: Koichiro Nakanishi, Hajime Hiratani
  • Patent number: 4500514
    Abstract: Human urine kallikrein dissolved in water is made heat-stable by the addition of a citric acid salt such as sodium citrate, so that an aqueous solution containing the kallikrein and the citric acid salt can be sterilized at 60.degree. to 70.degree. C.
    Type: Grant
    Filed: December 1, 1983
    Date of Patent: February 19, 1985
    Assignee: Japan Chemical Research Co., Ltd.
    Inventors: Koichiro Nakanishi, Hajime Hiratani
  • Patent number: 4479937
    Abstract: An anti-inflammatory agent comprising as an active component an inhibitor specifically inhibiting a thiol protease, which is obtained from human urine by extraction and purification. This agent has an action of inhibiting a disease caused by a thiol protease. This anti-inflammatory agent is prepared by a process in which a thiol protease inhibitor is extracted and purified from human urine by adopting in combination at least two treatments selected from a treatment with a molecular filter, a treatment with an ion exchanger, a treatment with an adsorber and an affinity chromatographic treatment.
    Type: Grant
    Filed: August 19, 1983
    Date of Patent: October 30, 1984
    Assignee: Zeria Shinyaku Kogyo Kabushiki Kaisha
    Inventors: Hiroshi Sato, Koji Sasaki, Kaname Takagi, Hajime Hiratani, Yoshikazu Yuki
  • Patent number: 4468344
    Abstract: Gastric acid secretion inhibiting substance obtainable from mammalian urine by conventional method is fractionated into the first and second components by gel filtration, adsorption and desorption on ion exchanger or electrophoresis detecting each component by biological test methods. The activities of the two components differ from each other in the biological tests.The first component is a glucoprotein-like substance of M.W. 100,000 and the second component is a peptide-like substance of M.W. about 6,000.
    Type: Grant
    Filed: January 27, 1983
    Date of Patent: August 28, 1984
    Assignee: Japan Chemical Research Co., Ltd.
    Inventors: Hajime Hiratani, Naomi Uchida, Toyohiko Nishimura
  • Patent number: 4303650
    Abstract: The invention provides a novel process for the production of erythropoietin, which is a promising medicine for curing anemia, from human urine containing the same. The inventive method comprises adjusting the pH value of the urine in the range from 6 to 8, if the pH value of the urine is out of this range, and contacting the thus pH-controlled urine with a specific adsorbent so as that the erythropoietin is selectively adsorbed on the adsorbent. The adsorbed erythropoietin is then eluted out by use of an eluant solution to give the product in a partially purified form.
    Type: Grant
    Filed: October 2, 1980
    Date of Patent: December 1, 1981
    Assignees: Ajinomoto Co., Inc., Japan Chemical Research Co., Ltd.
    Inventors: Kenji Takezawa, Hajime Hiratani